Zacks: Analysts Anticipate Supernus Pharmaceuticals Inc (SUPN) Will Announce Quarterly Sales of $108.07 Million

Wall Street analysts expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to post $108.07 million in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Supernus Pharmaceuticals’ earnings. The highest sales estimate is $110.63 million and the lowest is $103.67 million. Supernus Pharmaceuticals posted sales of $88.44 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 22.2%. The business is expected to report its next quarterly earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year sales of $401.02 million for the current financial year, with estimates ranging from $396.63 million to $403.60 million. For the next year, analysts anticipate that the company will post sales of $463.72 million, with estimates ranging from $450.92 million to $472.58 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that that provide coverage for Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.09. The company had revenue of $102.99 million for the quarter, compared to the consensus estimate of $100.75 million. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. Supernus Pharmaceuticals’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.29 earnings per share.

Several research firms have recently weighed in on SUPN. Cantor Fitzgerald restated an “overweight” rating on shares of Supernus Pharmaceuticals in a research report on Friday, November 23rd. ValuEngine downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 6th. BidaskClub downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 7th. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 11th. Finally, Cowen set a $55.00 target price on Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 30th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Supernus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $56.89.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. Glenmede Trust Co. NA lifted its position in Supernus Pharmaceuticals by 3.2% during the second quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock worth $39,070,000 after buying an additional 20,012 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in Supernus Pharmaceuticals by 28.1% during the third quarter. Janney Montgomery Scott LLC now owns 13,860 shares of the specialty pharmaceutical company’s stock worth $698,000 after buying an additional 3,039 shares in the last quarter. Icon Advisers Inc. Co. purchased a new position in Supernus Pharmaceuticals during the third quarter worth approximately $3,877,000. Oppenheimer Asset Management Inc. lifted its position in Supernus Pharmaceuticals by 9.2% during the third quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock worth $746,000 after buying an additional 1,251 shares in the last quarter. Finally, Cynosure Advisors LLC lifted its position in Supernus Pharmaceuticals by 55.0% during the second quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock worth $494,000 after buying an additional 2,930 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Shares of SUPN stock opened at $36.53 on Friday. The company has a market cap of $2.40 billion, a price-to-earnings ratio of 28.99, a price-to-earnings-growth ratio of 1.45 and a beta of 0.93. The company has a current ratio of 2.82, a quick ratio of 2.65 and a debt-to-equity ratio of 0.77. Supernus Pharmaceuticals has a 12-month low of $34.90 and a 12-month high of $61.25.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

See Also: Diversification

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply